Celcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity (CELC), a clinical-stage biotechnology company, has quietly surged more than 215% year-to-date, turning heads on ...

The Food and Drug Administration (FDA) has approved Truqap ™ (capivasertib) in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal ...

Find out how to take Fulvestrant(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

PATIENTS AND METHODS: Patients (n = 451) with advanced breast cancer were randomized to receive fulvestrant 250 mg as a once-monthly (one × 5 mL) intramuscular injection or an oral dose of anastrozole ...

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...

For fulvestrant to work well, the cells must also be responsive to estrogen, and producing the estrogen receptor ER-alpha. ER-alpha's importance to fulvestrant's anti-estrogenic action had been ...

The median time to treatment failure was 17.6 months in the fulvestrant arm and 12.7 months in the anastrozole arm, representing an HR of 0.73 (95% CI, 0.54-1.00).